{"title":"2019冠状病毒病大流行期间以亚临床心理情绪障碍为背景的语音职业功能性语音障碍治疗的发病基础","authors":"I. Sinaiko, Vasyl I. Troyan, Veronica M. Kryshtal","doi":"10.37219/2528-8253-2022-3-57","DOIUrl":null,"url":null,"abstract":"The aim of the research: Improvement of the traditional complex treatment of voice-speaking professions during the COVID-2019 pandemic with functional dysphonia on the background of subclinical psycho-emotional disorders by appointment neurotransmitter drugs.\nMaterials and methods: The study involved 49 people of voice-speech professions with functional disorders of the voice function of the hypotonic type, who were diagnosed with subclinical disorders of the psychoemotional state by questioning on the hospital anxiety and depression scale (HADS). Before and after treatment, voice disorders were diagnosed using perceptual evaluation of the GRBAS voice scale and video stroboscopy of the larynx. The impact of voice disorders on quality of life during the pandemic was assessed using the Voice COVID-19 (VC-19) questionnaire.\nAll patients received standardized treatment, which consisted of the use of metabolic, stimulant drugs, physiotherapy and instillation of drugs into the larynx. In 26 patients of the main group (MG), in addition to treatment, a neurotransmitterotropic drug (\"Beresh Magnesium plus B6\") was prescribed. The comparison group (CG) consisted of 23 people who received traditional therapy. Descriptive statistics were used for statistical analysis of the effectiveness of treatment, comparison of the difference in quantitative indicators by the method of nonparametric statistics using the Mann-Whitney-U-test.\nResults: The use of the neurotransmitter correction agent \"Beresh Magnesium plus B6\" by the patients with MG contributed to the suppression of their susceptibility to anxiety, stress and, as a result of these processes, made it possible to obtain, in comparison with the control group, a significant improvement in such indicators of acoustic parameters as voice strength by 5.78%, integral stroboscopy index - 13.34% and improvement of the quality of life by 34.03%, which indicates the effectiveness of the use of magnesium compounds with vitamin B6 in the complex treatment of patients with hypotonic dysphonia against the background of subclinical psychoemotional disorders.\nConclusions: Addit ional appointment of magnesium citrate and magnesium oxide compounds with vitamin B6, which has a modulating effect on neurotransmitters that affect depression and anxiety, to basic therapy for patients of main group, made it possible to obtain a significant improvement in the main perceptual and functional indicators of the voice and quality of life.","PeriodicalId":38742,"journal":{"name":"Otorhinolaryngology Clinics","volume":"22 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Etiopathogenetic grounding of the treatment of voice-speech professions with functional dysphonia on the background of subclinical psycho-emotional disorders during the COVID-2019 pandemic\",\"authors\":\"I. Sinaiko, Vasyl I. Troyan, Veronica M. Kryshtal\",\"doi\":\"10.37219/2528-8253-2022-3-57\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The aim of the research: Improvement of the traditional complex treatment of voice-speaking professions during the COVID-2019 pandemic with functional dysphonia on the background of subclinical psycho-emotional disorders by appointment neurotransmitter drugs.\\nMaterials and methods: The study involved 49 people of voice-speech professions with functional disorders of the voice function of the hypotonic type, who were diagnosed with subclinical disorders of the psychoemotional state by questioning on the hospital anxiety and depression scale (HADS). Before and after treatment, voice disorders were diagnosed using perceptual evaluation of the GRBAS voice scale and video stroboscopy of the larynx. The impact of voice disorders on quality of life during the pandemic was assessed using the Voice COVID-19 (VC-19) questionnaire.\\nAll patients received standardized treatment, which consisted of the use of metabolic, stimulant drugs, physiotherapy and instillation of drugs into the larynx. In 26 patients of the main group (MG), in addition to treatment, a neurotransmitterotropic drug (\\\"Beresh Magnesium plus B6\\\") was prescribed. The comparison group (CG) consisted of 23 people who received traditional therapy. Descriptive statistics were used for statistical analysis of the effectiveness of treatment, comparison of the difference in quantitative indicators by the method of nonparametric statistics using the Mann-Whitney-U-test.\\nResults: The use of the neurotransmitter correction agent \\\"Beresh Magnesium plus B6\\\" by the patients with MG contributed to the suppression of their susceptibility to anxiety, stress and, as a result of these processes, made it possible to obtain, in comparison with the control group, a significant improvement in such indicators of acoustic parameters as voice strength by 5.78%, integral stroboscopy index - 13.34% and improvement of the quality of life by 34.03%, which indicates the effectiveness of the use of magnesium compounds with vitamin B6 in the complex treatment of patients with hypotonic dysphonia against the background of subclinical psychoemotional disorders.\\nConclusions: Addit ional appointment of magnesium citrate and magnesium oxide compounds with vitamin B6, which has a modulating effect on neurotransmitters that affect depression and anxiety, to basic therapy for patients of main group, made it possible to obtain a significant improvement in the main perceptual and functional indicators of the voice and quality of life.\",\"PeriodicalId\":38742,\"journal\":{\"name\":\"Otorhinolaryngology Clinics\",\"volume\":\"22 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Otorhinolaryngology Clinics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37219/2528-8253-2022-3-57\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Otorhinolaryngology Clinics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37219/2528-8253-2022-3-57","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Etiopathogenetic grounding of the treatment of voice-speech professions with functional dysphonia on the background of subclinical psycho-emotional disorders during the COVID-2019 pandemic
The aim of the research: Improvement of the traditional complex treatment of voice-speaking professions during the COVID-2019 pandemic with functional dysphonia on the background of subclinical psycho-emotional disorders by appointment neurotransmitter drugs.
Materials and methods: The study involved 49 people of voice-speech professions with functional disorders of the voice function of the hypotonic type, who were diagnosed with subclinical disorders of the psychoemotional state by questioning on the hospital anxiety and depression scale (HADS). Before and after treatment, voice disorders were diagnosed using perceptual evaluation of the GRBAS voice scale and video stroboscopy of the larynx. The impact of voice disorders on quality of life during the pandemic was assessed using the Voice COVID-19 (VC-19) questionnaire.
All patients received standardized treatment, which consisted of the use of metabolic, stimulant drugs, physiotherapy and instillation of drugs into the larynx. In 26 patients of the main group (MG), in addition to treatment, a neurotransmitterotropic drug ("Beresh Magnesium plus B6") was prescribed. The comparison group (CG) consisted of 23 people who received traditional therapy. Descriptive statistics were used for statistical analysis of the effectiveness of treatment, comparison of the difference in quantitative indicators by the method of nonparametric statistics using the Mann-Whitney-U-test.
Results: The use of the neurotransmitter correction agent "Beresh Magnesium plus B6" by the patients with MG contributed to the suppression of their susceptibility to anxiety, stress and, as a result of these processes, made it possible to obtain, in comparison with the control group, a significant improvement in such indicators of acoustic parameters as voice strength by 5.78%, integral stroboscopy index - 13.34% and improvement of the quality of life by 34.03%, which indicates the effectiveness of the use of magnesium compounds with vitamin B6 in the complex treatment of patients with hypotonic dysphonia against the background of subclinical psychoemotional disorders.
Conclusions: Addit ional appointment of magnesium citrate and magnesium oxide compounds with vitamin B6, which has a modulating effect on neurotransmitters that affect depression and anxiety, to basic therapy for patients of main group, made it possible to obtain a significant improvement in the main perceptual and functional indicators of the voice and quality of life.
期刊介绍:
Otorhinolaryngology Clinics: An International Journal is an International periodical devoted at exploring connections between clinical experience and world literature, and understanding of various pathologies and diseases related to the ear, nose and throat. Issues of recent advancements and research related to disease, illness, health and medical science are examined through various evidence-based clinical research studies. This journal proposes to serve as a collection of clinical notes, with an international perspective, along with the recent advances for postgraduates and consultants. The readership for this journal would include a wide variety of healthcare professionals, such as otolaryngologists, head and neck surgeons, ENT nurses as well as scholars and academicians in the field of medicine, trauma, surgery, etc. This journal aims to encourage the analysis of clinical data from various centers all over the world using standardized protocols to develop an international consensual perspective on the management of disorders related to the field of otorhinolaryngology. Recently, we have introduced "Case Reports", "How I Do It" and "Original Research" categories in the process of expanding the scope of the journal. Thisis a peer-reviewed journal of which three issues would be published each year. Each future issue will cover a different topic of special interest in the field of otorhinolaryngology and head and neck surgery. This issue is the first of its kind dedicated to "anesthesia in otorhinolaryngology" and contains a compilation of articles by experienced anesthesiologists dealing with a large volume of ENT and related surgeries. In each issue, the editors give their perspective based on the submitted articles. All non invited articles are peer-reviewed. Peer-revieweing helps in providing unbiased, independent, critical assessment of the results of the research study in question including the scientific process.